[row][paragraph_left]Monitoring immune responses in cancer therapies: Avoiding the cytokine storm and other negative outcomes – Now Complimentary on Demand
In case you missed our live, online educational seminar, “Monitoring immune responses in cancer therapies: Avoiding the cytokine storm and other negative outcomes” we wanted to let you know that it is available in our complimentary on-demand archive.
You can access this archive to watch the webinar at any time.
For more information and access to the archive, go to:
About This Webinar
Immunotherapy is rapidly becoming the go-to treatment for a growing number of cancers. Despite this, the technology is not without its challenges. Considerable success has been achieved in engineering immune cells to evade the suppressive effects of cancer and kill malignant cells. However, researchers are still learning how best to implement immunotherapy regimens, making monitoring of the immune response during treatment development and implementation critical to predicting how the modified cells will function, and how the immune system as a whole will react. Will the engineered cells have the desired effect? And will these cells stimulate unwanted reactions, such as cytokine-release syndrome or a “cytokine storm”? Understanding when, where, and why cytokines are released will allow safer, more effective therapies to be developed. This webinar will offer insights from leaders in the field about the importance of monitoring the immune response and how this can best be done.During the webinar, the viewers will:
• Learn about the most recent advances in immunotherapy and the impact of these treatments on the immune system
• Gain insight into methods for monitoring immune response following immunotherapy treatment.
Gordon J. Freeman
Dana-Farber Cancer Institute, Harvard Medical School
Michel Sadelain, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center
New York, NY
Questions? E-mail: email@example.com.
Produced by the Science/AAAS Custom Publishing Office and sponsored by Bio-Techne.